Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2017

View Archived Issues

mGlu4 receptor found as a target for treating maladaptive impulsivity

PhoenixMD reports favorable preclinical data on RSK inhibitor for TNBC

FDA advisory committee recommends approval of Pfizer's epoetin alfa biosimilar

Orexin OX2 receptor agonist as promising new therapeutic approach for narcolepsy-cataplexy symptoms

Hovione begins phase I study of HY-02

Lundbeck patents P2X7 receptor antagonists

Hubei Biological Medicine Industrial Technology Institute and collaborator divulge ALK inhibitors

Jiangsu Hansoh Pharmaceutical Group identifies compounds against HCV

Merck KGaA discovers PARP-1 and TANK1/2 inhibitors

Roche presents equilibrative nucleoside transporter 1 inhibitors

Ciprofloxacin DPI benefit not significant in phase III bronchiectasis trial

FDA grants priority review to axicabtagene ciloleucel BLA

FDA grants approval for expanded use of Zykadia in first-line ALK-positive metastatic NSCLC

FDA issues complete response letter for SUN-101/eFlow

Valerion Therapeutics begins recruitment in phase I/II trial of VAL-1221

ENaC inhibitor AZD-5634 shows reduced potential for side effects in first-in-human study

Targeting KLF5 for the treatment of colorectal cancer

FDA grants orphan designation to liposome irinotecan injection for small cell lung cancer

Model recapitulates features of chronic human empyema

Galderma's resiquimod named U.S. orphan drug for cutaneous T-cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...